Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 5Recurrence 2Lymphoma, T-Cell, Peripheral 2Lymphoma 2Immunoblastic Lymphadenopathy 2Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Large Granular Lymphocytic 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Cyclophosphamide 5Specimen Handling 4Magnetic Resonance Spectroscopy 4Biopsy 4Nivolumab 3sodium-iodide symporter 2fludarabine 2cemiplimab 2X-Rays 2Whole-Body Irradiation 2Stem Cell Transplantation 2Photons 2Mycophenolic Acid 2Immunoglobulin G 2Disulfides 2Cyclosporine 210-propargyl-10-deazaaminopterin 2treosulfan 1talimogene laherparepvec 1sargramostim 1ruxolitinib 1pembrolizumab 1fludarabine phosphate 1entrectinib 1duvelisib 1ceritinib 1belinostat 1alectinib 1Vincristine 1Vinblastine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large-Cell, Anaplastic × duvelisib × 90 days × Clear all
NCT07001384 2026-05-26

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
30 enrolled
Lymphoid

Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡